G

Galderma Group AG
SIX:GALD

Watchlist Manager
Galderma Group AG
SIX:GALD
Watchlist
Price: 97 CHF 0.83% Market Closed
Market Cap: 23B CHF
Have any thoughts about
Galderma Group AG?
Write Note

Net Margin
Galderma Group AG

-1.4%
Current
-3%
Average
3.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.4%
=
Net Income
-57.2m
/
Revenue
4.1B

Net Margin Across Competitors

Country CH
Market Cap 23B CHF
Net Margin
-1%
Country CA
Market Cap 559.6B CAD
Net Margin N/A
Country US
Market Cap 94.4B USD
Net Margin
4%
Country NL
Market Cap 85B Zac
Net Margin
63%
Country ID
Market Cap 667.2T IDR
Net Margin
27%
Country US
Market Cap 39.5B EUR
Net Margin
4%
Country US
Market Cap 29.7B USD
Net Margin
-48%
Country IN
Market Cap 1.9T INR
Net Margin
123%
Country ZA
Market Cap 21.3B Zac
Net Margin
99%
Country ZA
Market Cap 19.1B Zac
Net Margin
116%
Country ZA
Market Cap 17.4B Zac
Net Margin
40%
No Stocks Found

Galderma Group AG
Glance View

Market Cap
23B CHF
Industry
N/A

Galderma Group AG, a prominent player in the dermatological field, has carved a niche for itself since its inception in 1981 as a joint venture between Nestlé and L'Oréal. Now operating independently, Galderma journeys through the complex terrain of skin health, focusing keenly on prescription drugs, over-the-counter products, and aesthetics medicine. Its spectrum of offerings spans across dermatology segments—from treating acne and rosacea to pioneering advances in aesthetic treatments with its products like Restylane and Dysport. The company's core strategy revolves around leveraging its extensive R&D capabilities, ensuring that medical and aesthetic practitioners have cutting-edge solutions that address both therapeutic and enhancement demands. Revenue streams for Galderma primarily flow from its three business pillars—prescription, aesthetics, and consumer health solutions. The prescription segment engages dermatologists and healthcare providers, offering topicals and oral medications pivotal for serious skin conditions. The aesthetics division appeals to clinics and practitioners focusing on beauty and corrective procedures, while consumer health offers OTC solutions direct to customers for daily skin concerns. Galderma capitalizes on strategic alliances and partnerships, ensuring robust distribution channels, and invests heavily in innovation, staying at the forefront of the fast-evolving dermatology landscape. With a presence in over 100 countries, Galderma has made a mark by blending medical rigor with consumer accessibility, anchoring its success in its in-depth understanding of skin health and nuanced market needs.

GALD Intrinsic Value
Not Available
G

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.4%
=
Net Income
-57.2m
/
Revenue
4.1B
What is the Net Margin of Galderma Group AG?

Based on Galderma Group AG's most recent financial statements, the company has Net Margin of -1.4%.